Inventaire - your friends and communities are your best library

Montelukast improves symptoms of seasonal allergic rhinitis over a 4‐week treatment period

Published in: Allergy

Date of publication: December 1, 2003

Language: English

Main subject: allergic rhinitis, seasonal allergic rhinitis, immunology

Bibliographic databases:

Cites articles 21

Date

Title

Authors

September 1, 1990

Nasal physiology and inflammatory mediators during natural pollen exposure
January 1, 1991

Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis
June 1, 1993

Comparison of the secretory response of the nasal mucosa to methacholine and histamine
February 1, 1994

Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents
May 1, 1994

Effect of magnitude of airway responsiveness and therapy with inhaled corticosteroid on histamine tachyphylaxis in asthma
March 1, 1995

Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure
April 1, 1996

Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis
February 1, 1997

Measuring health-related quality of life in rhinitis
November 1, 1999

American Thoracic Society Workshop. Immunobiology of asthma and rhinitis. Pathogenic factors and therapeutic options
August 1, 1999

Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults
March 1, 1999

Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis
July 1, 1999

Nasal response to a single antigen challenge in patients with allergic rhinitis - inflammatory cell recruitment persists up to 48 hours
May 1, 1999

Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis
February 1, 2000

Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease".
May 1, 2000

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial
June 1, 2000

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group
January 1, 2000

Antiallergic effects of H1-receptor antagonists
November 1, 2001

Allergic rhinitis and its impact on asthma
January 1, 2001

Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years
June 1, 2002

Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall
July 1, 2002

Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring

Article -

Welcome to inventaire

The library of your friends and communities

Learn more